Dear Non-registered Shareholder(s)(Note 1) , 26 September 2025 The following document(s) of China Biotech Services Holdings Limited ("Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.cbshhk.com and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Interim Report 2025 You may at any time send your request in writing to the Company (c/o its Hong Kong Branch Share Registrar, Union Registrars Limited ("Hong ...

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 (Incorporated in the Cayman Islands and continued in Bermuda with limited liability) （於開曼群島註冊成立並在百慕達繼續營業之有限公司） (Stock Code 股份代號: 8037) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 26 September 2025 各位登記股東： 中國生物科技服務控股有限公司（「本公司」）下述文件已以中、英文版本編制及於本公司之網站 (www.cbshhk.com) 及香港聯合交易所有限公司之網 站 (www.hkexnews.hk) （統稱「該等網站」）刊載:- • 中期報告 2025 如 閣下並未提供電郵地址或電郵地址無效，並現在希望收取有關公司通訊於該等網站發佈的電郵通知，以代替日後書面通知印刷本，請 閣下填妥本 函背面的回條，並在回條上填寫所需資料及簽名，然後把回條以電郵至 8037-corpcomm@uni ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 38,872,000, an increase of 19.0% compared to HKD 32,449,000 for the same period in 2024[4] - Gross profit for the same period was HKD 2,542,000, a significant recovery from a gross loss of HKD 3,107,000 in 2024[4] - Operating loss decreased to HKD 19,308,000 from HKD 124,588,000 year-on-year, indicating improved operational efficiency[4] - The net loss attributable to owners of the company was HKD 32,006,000, down from HKD 79,917,000 in the previous year, reflecting a 59.9% reduction[5] - The company reported a basic and diluted loss per share of HKD 0.033, an improvement from HKD 0.083 in the previous year[5] - Other comprehensive income for the period was HKD 6,251,000, compared to a loss of HKD 7,242,000 in 2024, showing a positive shift in financial performance[5] - The total comprehensive loss for the period was HKD (30,502) thousand, which includes a loss of HKD (36,753) thousand attributable to owners of the company[10] - The group recorded a loss of approximately HKD 36,753,000 for the six months ended June 30, 2025, compared to a loss of HKD 125,731,000 for the same period in 2024[18][24] Assets and Liabilities - Total assets as of June 30, 2025, amounted to HKD 538,426,000, a slight increase from HKD 529,955,000 at the end of 2024[8] - Non-current assets increased to HKD 502,598,000 from HKD 466,860,000, primarily driven by growth in property, plant, and equipment[7] - Current liabilities rose to HKD 195,691,000 from HKD 192,614,000, indicating a stable liquidity position despite increased operational activities[8] - The group has total borrowings and lease liabilities of approximately HKD 161,096,000 and HKD 9,418,000, respectively, with cash and bank balances of only HKD 11,290,000[18][19] - As of June 30, 2025, total equity attributable to owners of the company was HKD 211,886 thousand, down from HKD 242,388 thousand at the beginning of the period[10] - The company’s accumulated losses increased to HKD (566,473) thousand as of June 30, 2025, compared to HKD (534,467) thousand at the beginning of the period[10] Cash Flow - For the six months ended June 30, 2025, the net cash used in operating activities was HKD (4,936) thousand, a significant improvement from HKD (95,539) thousand in the same period of 2024[12] - The net cash used in investing activities for the same period was HKD (22,769) thousand, compared to HKD (61,468) thousand in 2024, indicating a reduction in investment outflows[12] - Financing activities generated a net cash inflow of HKD 23,128 thousand, down from HKD 118,558 thousand in the previous year, reflecting a decrease in financing activities[12] Operational Efficiency - The company continues to focus on research and development, with R&D expenses reduced to HKD 5,965,000 from HKD 17,593,000, reflecting a strategic shift towards cost management[4] - Sales and distribution expenses decreased by approximately 44.6%, from about HKD 6.5 million to HKD 3.6 million, primarily due to reduced employee costs during the reporting period[80] - Administrative expenses for the first half of 2025 were approximately HKD 34.0 million, a decrease of about 52.0% compared to HKD 70.9 million in the first half of 2024, primarily due to reduced employee costs and a one-time legal claim in the previous period[82] Segment Performance - Revenue from medical laboratory testing and health check services was HKD 16,164,000, down 18.5% from HKD 19,729,000 in the previous year[21][24] - Insurance brokerage services generated revenue of HKD 22,640,000, a significant increase of 84.5% compared to HKD 12,255,000 in the prior year[21][24] - The group reported a segment loss of HKD 18,320,000 for the six months ended June 30, 2025, compared to a segment loss of HKD 100,949,000 for the same period in 2024[24] Financing and Capital Structure - The group is actively seeking alternative financing options, including share placements and issuing convertible bonds, to strengthen equity and support growth[20] - The company issued convertible bonds totaling USD 6,000,000 (approximately HKD 47,100,000) on December 27, 2024, with a conversion price of HKD 1.20 per share[49] - As of June 30, 2025, the liability component of the convertible bonds was HKD 42,919,000, an increase from HKD 41,635,000 as of December 31, 2024[50] - Bank borrowings rose to HKD 33,981,000 as of June 30, 2025, compared to HKD 25,981,000 as of December 31, 2024, reflecting an increase of 30.5%[53] - Total borrowings increased to HKD 161,096,000 as of June 30, 2025, up from HKD 138,693,000 as of December 31, 2024, representing a growth of 16.1%[53] Strategic Initiatives - The company is collaborating with AXA Insurance to develop a comprehensive medical insurance product covering boron neutron capture therapy costs, aimed at increasing public awareness and accessibility[91] - Partnerships have been established with leading hospitals to facilitate patient referrals to the boron neutron capture therapy center, enhancing awareness and accessibility for cancer patients[92] - The company aims to commercialize LY007 and accelerate its development, including entering into domestic phase II clinical trials and commercial partnerships[101] Corporate Governance - The audit committee has reviewed the group's unaudited interim results for the period and confirmed compliance with applicable accounting standards and GEM listing rules[162] - The company has maintained high standards of corporate governance and compliance with legal and regulatory requirements[156] - The board consists of four executive directors and three independent non-executive directors as of August 27, 2025[169]

Core Viewpoint - China Biotechnology Services (08037) announced a loan agreement to support the construction of a boron neutron capture therapy center, aiming to provide cancer treatment services by the end of 2025 [1] Group 1: Loan Agreement - The company’s indirect wholly-owned subsidiary, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd., entered into a loan contract with Hainan Rural Commercial Bank, with a maximum principal amount of RMB 180 million [1] - The loan will facilitate the establishment of the boron neutron capture therapy center [1] Group 2: Future Plans - The center is expected to open and commence operations by the end of 2025, targeting cancer patients in need of boron neutron therapy services [1] - The company aims to develop a network of boron neutron capture therapy centers across China, leveraging the supportive policies of the Boao Lecheng Pilot Zone and establishing franchised hospitals to generate additional revenue [1]

Core Viewpoint - China Biotechnology Services (08037) has announced a loan agreement to support the construction of a boron neutron capture therapy center, aiming to provide cancer treatment services by the end of 2025 [1] Group 1: Loan Agreement - The company has entered into a loan contract with Hainan Rural Commercial Bank, with a maximum principal amount of RMB 180 million [1] - The loan will assist in the establishment of the boron neutron capture therapy center [1] Group 2: Future Plans - The center is expected to open and commence operations by the end of 2025, targeting cancer patients in need of boron neutron therapy [1] - The company aims to develop a network of boron neutron capture therapy centers across China, leveraging the supportive policies of the Boao Lecheng Pilot Zone [1] - Plans include the development of franchised hospitals to generate additional revenue [1]

CHINA BIOTECH SERVICES HOLDINGS LIMITED 中國生物科技服務控股有限公司 （於開曼群島註冊成立並在百慕達繼續營業之有限公司） （股份代號：8037） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 保證 ： (1) 抵押鵬博（海南）名下位於博鰲樂城先行區的土地使用權、 地上在建工程，以及硼中子治療的醫療設備； 反擔保 ： 鑑於第三方擔保人為該貸款提供保證擔保，本公司將向第三 方擔保人提供連帶責任保證，且鵬博（海南）的直接控股公司 將質押鵬博（海南）的100%股權予第三方擔保人，作為反擔保。 自願公告 銀行向本公司附屬公司授出貸款 本公告乃由中國生物科技服務控股有限公司（「本公司」，連同其附屬公司，統稱 為「本集團」）作出之自願公告。 本公司之董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月九日，鵬博（海 南）硼中子醫療科技有限公司（「鵬博（海南）」）（於中華人民共和國（「中國」）成立 之有限公司，並於本公告 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CHINA BIOTECH SERVICES HOLDINGS LIMITED （股份代號：8037） 補充公告 須予披露的交易 一名投資者投資本公司附屬公司 謹此提述中國生物科技服務控股有限公司日期為二零二五年七月十一日之公告， 內容有關華大松禾投資於鵬博（海南）（「該公告」）。除文義另有所指外，於本公告 內所採用之詞彙與該公告內所界定者具有相同涵義。 本公司謹此就該投資提供以下補充資料。 交易架構 根據中國相關法律法規，中國企業須就其企業境外投資(ODI)向相關中國政府機關 完成若干備案（包括向地方發展和改革委員會備案以及其後向地方外匯管理局登 記）。有關備案乃為監管及監察中國企業或個人所作出的境外直接投資。由於華 大松禾（為中國企業）正透過認購Dynamic Healthcare（其為一家在英屬處女群島註 冊成立之公司）的股份進行境外直接投資，因此，該投資須進行企業境外投資備案， 其一般需要一至三個 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物科技服務控股有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08037 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.1 | HKD | | 200,000,000 | 本月底法定/ ...

Core Viewpoint - China Biotechnology Services (08037.HK) reported a significant improvement in financial performance for the six months ending June 30, 2025, with a revenue increase of 19.8% year-on-year, indicating effective cost control measures and compensation income from insurance claims [1] Financial Performance - Revenue reached HKD 38.872 million, up 19.8% compared to the previous year [1] - Gross profit was HKD 2.542 million, a recovery from a gross loss of HKD 3.107 million in the same period last year [1] - The loss attributable to owners of the company was HKD 32.006 million, a significant reduction of 60.0% from HKD 79.917 million in the prior year [1] - Basic loss per share was HKD 0.033 [1] Operational Improvements - The improvement in operational performance was primarily due to successful implementation of cost control measures, leading to an increase in gross margin and a reduction in administrative expenses [1] - The company received approximately HKD 13.7 million in compensation income related to damages from heavy rainfall affecting construction sites in Hainan during 2024 [1]

Core Insights - China Biotechnology Services (08037) reported a mid-year revenue of HKD 38.872 million for 2025, representing a year-on-year increase of 19.79% [1] - The company recorded a loss attributable to shareholders of HKD 32.006 million, which is a reduction of 59.95% compared to the previous year [1] - The loss per share is HKD 0.033 [1] Financial Performance - Revenue for the first half of 2025 reached HKD 38.872 million, showing a growth of 19.79% year-on-year [1] - The loss attributable to shareholders decreased significantly by 59.95%, amounting to HKD 32.006 million [1] - The earnings per share were reported at HKD 0.033 [1] Key Factors for Improvement - The improvement in loss is primarily attributed to successful cost control measures implemented by the company, which led to an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 13.7 million related to insurance claims for damages caused by heavy rainfall affecting construction sites in Hainan in 2024 [1]